Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
World game at war: why some European nations have threatened a World Cup boycott 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
CANTON, Mass., April 20, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 799-9797. An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
